Caffeine enhances doxorubicin cardiac toxicity in an animal model

Jeffrey D. Hosenpud, Jay Wright, Leonard Simpson, Jonathan J. Abramson

    Research output: Contribution to journalArticle

    4 Citations (Scopus)

    Abstract

    Based on in vitro data suggesting an interaction between methylxanthines and doxorubicin in regulating Ca2+ across muscle sarcoplasmic reticulum, this study was designed to test the hypothesis that a commonly used methylxanthine, caffeine, might influence the cardiac toxicity of doxorubicin. Three days following doxorubicin treatment, in vivo intracardiac pressures, cardiac outputs, in vitro cardiac weights, and cardiac electron microscopy were performed. Guinea pigs were treated with doxorubicin alone, doxorubicin plus caffeine, caffeine alone, and sterile saline as a control measure. Animals treated with doxorubicin had no significant differences in in vivo hemodynamics compared to the control animals. The average histology score was slightly but not statistically greater than the control animals, score (1.19 ± 0.36 vs 1.60 ± 0.34, respectively, P = NS). Animals receiving both doxorubicin and caffeine compared to the control animals had important differences in left ventricular systolic pressure (67 ± 10 vs 92 ± 7 mmHg; P = .003), cardiac output (154 ± 35 vs 217 ± 41 mL/min; P = .0174), stroke volume (.59 ± 12 vs .79 ± .07 mL; P = .0045), and histology score (2.36 ± 0.21 vs 1.19 ± 0.36; P = .028). There were no differences in left or right heart filling pressures between treatment groups. As an independent confirmation, there was a weak but statistically significant negative correlation between the biopsy score and cardiac output or stroke volume for all four groups of animals (r = .44, P = .031 and r = -.42, P = .040, respectively). These data are consistent with caffeine and doxorubicin having additive or potentiating effects on cardiac toxicity in this animal model.

    Original languageEnglish (US)
    Pages (from-to)155-160
    Number of pages6
    JournalJournal of Cardiac Failure
    Volume1
    Issue number2
    DOIs
    StatePublished - 1995

    Fingerprint

    Caffeine
    Doxorubicin
    Animal Models
    Cardiac Output
    Stroke Volume
    Histology
    Pressure
    Cardiac Volume
    Cardiotoxicity
    Sarcoplasmic Reticulum
    Ventricular Pressure
    Electron Microscopy
    Guinea Pigs
    Hemodynamics
    Blood Pressure
    Biopsy
    Weights and Measures
    Muscles
    Therapeutics

    Keywords

    • animal model
    • caffeine toxicity
    • doxorubicin
    • heart failure

    ASJC Scopus subject areas

    • Cardiology and Cardiovascular Medicine

    Cite this

    Caffeine enhances doxorubicin cardiac toxicity in an animal model. / Hosenpud, Jeffrey D.; Wright, Jay; Simpson, Leonard; Abramson, Jonathan J.

    In: Journal of Cardiac Failure, Vol. 1, No. 2, 1995, p. 155-160.

    Research output: Contribution to journalArticle

    Hosenpud, JD, Wright, J, Simpson, L & Abramson, JJ 1995, 'Caffeine enhances doxorubicin cardiac toxicity in an animal model', Journal of Cardiac Failure, vol. 1, no. 2, pp. 155-160. https://doi.org/10.1016/1071-9164(95)90017-9
    Hosenpud, Jeffrey D. ; Wright, Jay ; Simpson, Leonard ; Abramson, Jonathan J. / Caffeine enhances doxorubicin cardiac toxicity in an animal model. In: Journal of Cardiac Failure. 1995 ; Vol. 1, No. 2. pp. 155-160.
    @article{a6205371c5304a099ffbd8f3d2eb08c3,
    title = "Caffeine enhances doxorubicin cardiac toxicity in an animal model",
    abstract = "Based on in vitro data suggesting an interaction between methylxanthines and doxorubicin in regulating Ca2+ across muscle sarcoplasmic reticulum, this study was designed to test the hypothesis that a commonly used methylxanthine, caffeine, might influence the cardiac toxicity of doxorubicin. Three days following doxorubicin treatment, in vivo intracardiac pressures, cardiac outputs, in vitro cardiac weights, and cardiac electron microscopy were performed. Guinea pigs were treated with doxorubicin alone, doxorubicin plus caffeine, caffeine alone, and sterile saline as a control measure. Animals treated with doxorubicin had no significant differences in in vivo hemodynamics compared to the control animals. The average histology score was slightly but not statistically greater than the control animals, score (1.19 ± 0.36 vs 1.60 ± 0.34, respectively, P = NS). Animals receiving both doxorubicin and caffeine compared to the control animals had important differences in left ventricular systolic pressure (67 ± 10 vs 92 ± 7 mmHg; P = .003), cardiac output (154 ± 35 vs 217 ± 41 mL/min; P = .0174), stroke volume (.59 ± 12 vs .79 ± .07 mL; P = .0045), and histology score (2.36 ± 0.21 vs 1.19 ± 0.36; P = .028). There were no differences in left or right heart filling pressures between treatment groups. As an independent confirmation, there was a weak but statistically significant negative correlation between the biopsy score and cardiac output or stroke volume for all four groups of animals (r = .44, P = .031 and r = -.42, P = .040, respectively). These data are consistent with caffeine and doxorubicin having additive or potentiating effects on cardiac toxicity in this animal model.",
    keywords = "animal model, caffeine toxicity, doxorubicin, heart failure",
    author = "Hosenpud, {Jeffrey D.} and Jay Wright and Leonard Simpson and Abramson, {Jonathan J.}",
    year = "1995",
    doi = "10.1016/1071-9164(95)90017-9",
    language = "English (US)",
    volume = "1",
    pages = "155--160",
    journal = "Journal of Cardiac Failure",
    issn = "1071-9164",
    publisher = "Churchill Livingstone",
    number = "2",

    }

    TY - JOUR

    T1 - Caffeine enhances doxorubicin cardiac toxicity in an animal model

    AU - Hosenpud, Jeffrey D.

    AU - Wright, Jay

    AU - Simpson, Leonard

    AU - Abramson, Jonathan J.

    PY - 1995

    Y1 - 1995

    N2 - Based on in vitro data suggesting an interaction between methylxanthines and doxorubicin in regulating Ca2+ across muscle sarcoplasmic reticulum, this study was designed to test the hypothesis that a commonly used methylxanthine, caffeine, might influence the cardiac toxicity of doxorubicin. Three days following doxorubicin treatment, in vivo intracardiac pressures, cardiac outputs, in vitro cardiac weights, and cardiac electron microscopy were performed. Guinea pigs were treated with doxorubicin alone, doxorubicin plus caffeine, caffeine alone, and sterile saline as a control measure. Animals treated with doxorubicin had no significant differences in in vivo hemodynamics compared to the control animals. The average histology score was slightly but not statistically greater than the control animals, score (1.19 ± 0.36 vs 1.60 ± 0.34, respectively, P = NS). Animals receiving both doxorubicin and caffeine compared to the control animals had important differences in left ventricular systolic pressure (67 ± 10 vs 92 ± 7 mmHg; P = .003), cardiac output (154 ± 35 vs 217 ± 41 mL/min; P = .0174), stroke volume (.59 ± 12 vs .79 ± .07 mL; P = .0045), and histology score (2.36 ± 0.21 vs 1.19 ± 0.36; P = .028). There were no differences in left or right heart filling pressures between treatment groups. As an independent confirmation, there was a weak but statistically significant negative correlation between the biopsy score and cardiac output or stroke volume for all four groups of animals (r = .44, P = .031 and r = -.42, P = .040, respectively). These data are consistent with caffeine and doxorubicin having additive or potentiating effects on cardiac toxicity in this animal model.

    AB - Based on in vitro data suggesting an interaction between methylxanthines and doxorubicin in regulating Ca2+ across muscle sarcoplasmic reticulum, this study was designed to test the hypothesis that a commonly used methylxanthine, caffeine, might influence the cardiac toxicity of doxorubicin. Three days following doxorubicin treatment, in vivo intracardiac pressures, cardiac outputs, in vitro cardiac weights, and cardiac electron microscopy were performed. Guinea pigs were treated with doxorubicin alone, doxorubicin plus caffeine, caffeine alone, and sterile saline as a control measure. Animals treated with doxorubicin had no significant differences in in vivo hemodynamics compared to the control animals. The average histology score was slightly but not statistically greater than the control animals, score (1.19 ± 0.36 vs 1.60 ± 0.34, respectively, P = NS). Animals receiving both doxorubicin and caffeine compared to the control animals had important differences in left ventricular systolic pressure (67 ± 10 vs 92 ± 7 mmHg; P = .003), cardiac output (154 ± 35 vs 217 ± 41 mL/min; P = .0174), stroke volume (.59 ± 12 vs .79 ± .07 mL; P = .0045), and histology score (2.36 ± 0.21 vs 1.19 ± 0.36; P = .028). There were no differences in left or right heart filling pressures between treatment groups. As an independent confirmation, there was a weak but statistically significant negative correlation between the biopsy score and cardiac output or stroke volume for all four groups of animals (r = .44, P = .031 and r = -.42, P = .040, respectively). These data are consistent with caffeine and doxorubicin having additive or potentiating effects on cardiac toxicity in this animal model.

    KW - animal model

    KW - caffeine toxicity

    KW - doxorubicin

    KW - heart failure

    UR - http://www.scopus.com/inward/record.url?scp=0029257855&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0029257855&partnerID=8YFLogxK

    U2 - 10.1016/1071-9164(95)90017-9

    DO - 10.1016/1071-9164(95)90017-9

    M3 - Article

    C2 - 9420645

    AN - SCOPUS:0029257855

    VL - 1

    SP - 155

    EP - 160

    JO - Journal of Cardiac Failure

    JF - Journal of Cardiac Failure

    SN - 1071-9164

    IS - 2

    ER -